EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Laekna's enterprise value is HK$7,560.58 Mil.
Laekna's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil. Therefore, Laekna's EV-to-Revenue for today is .
The historical rank and industry rank for Laekna's EV-to-Revenue or its related term are showing as below:
HKSE:02105's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.39 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2025-06-03), Laekna's stock price is HK$19.80.
Laekna's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00. Therefore, Laekna's PS Ratio for today is .
Laekna EV-to-Revenue Historical Data
The historical data trend for Laekna's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Laekna's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laekna's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Laekna's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Laekna's EV-to-Revenue falls into.
Laekna's current Enterprise Value is HK$7,560.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Laekna's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laekna's share price for today is HK$19.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laekna EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Laekna's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02105 has been successfully added to your